During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
|Videos|May 14, 2018
Treating High-Risk Multiple Myeloma
Treating High-Risk Multiple Myeloma
Advertisement
- A 74-year-old woman was admitted to the ICU with pneumococcal bacteremia. She complained of recent severe fatigue, loss of appetite, nausea
- History: chronic HTN, aortic insufficiency, diabetes mellitus
- X-ray of the pelvis showed numerous lytic lesions in the ilium and a large lesion in the right proximal femur
- MRI confirmed a 9-mm lesion in the right femoral head and numerous bilateral T1 hypointense and T2 hyperintense lesions in both iliac region
- Laboratory results:
- Hb, 8.3 g/dL
- Ca2+16.35 mg/dL
- Creatinine, 1.0 mg/dL
- Creatinine clearance, 59 mL/min
- M-protein, 1.6 g/dL
- B2M, 4.9 mcg/mL
- SFLC, kappa, 150 mg/L
- Bone marrow biopsy, 70% plasma cells
- Molecular testing, t(4;14)
- ECOG 2
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5